Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385.
BACKGROUND
We have previously shown that a new measles, mumps, rubella (MMR) vaccine, Priorix, with a novel mumps component elicits anti-mumps antibody titers comparable to the licensed M-M-R II vaccine.


METHODS
To ensure that these antibodies had neutralizing activity against wild-type mumps virus, sera were prepared 2 and 18 months after vaccination of 12-24-month-old infants with either Priorix or M-M-R II and ELISA antibody titers and neutralizing activity were determined.


RESULTS
After 2 months, Priorix and M-M-R II vaccines elicited comparable ELISA antibody titers and neutralizing activity. At 18 months ELISA seropositivity rates were 80-81% and 94-96% of vaccinees had neutralizing activity. All ELISA seropositives had neutralizing activity.


CONCLUSIONS
These data suggest that both vaccines provided equivalent protection against mumps over this 18-month period.
Usonis
V
V
Centre of Pediatrics, Vilnius University, Lithuania. usonis@ktl.mii.lt
Bakasenas
V
V
Denis
M
M
D000917:Antibody Formation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D022542:Measles-Mumps-Rubella Vaccine / Q000276:immunology*; D009109:Mumps virus / Q000276:immunology* / Q000472:pathogenicity; D009500:Neutralization Tests; D014611:Vaccination
D022542:Measles-Mumps-Rubella Vaccine